Neurocrine Biosciences(NBIX)

SAN DIEGO, CABiotechnology1 H-1B visas (FY2023)

Focus: Neurocrine is a San Diego-based specialty biotech with 1,001-5,000 employees focused on neurology and endocrinology therapeutics. The company is publicly traded (NBIX) with $1.9B in FY2025 revenue, predominantly driven by its lead asset INGREZZA.

Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Employees

1001-5000

Open Jobs

113-13 this month

Cooling — net -13 jobs in 30d

131 added, 144 removed. Slower than typical.

Should You Work at Neurocrine Biosciences?

AI assessment

Neurocrine offers stability through a mature blockbuster and growth optionality via a deep pipeline, but career trajectory depends on pipeline success and your comfort with single-product-company risk.

Why Work Here

Single blockbuster product (INGREZZA) generating $1.7B in Part D spending with peak lifecycle status and patent protection until 2040, providing revenue stability.

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$1.9B

Key Products

INGREZZA

Tardive Dyskinesia, Huntington's Disease, Tourette Syndrome

$1.7B Part D

Peak

Help build intelligence for Neurocrine Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Ag

Tardive Dyskinesia

N/A

Clinical Trials (1)

NCT03062033Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

N/A

Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies

Parkinson's Disease

N/A

Clinical Trials (1)

NCT03733496Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies

N/A

Telemedicine Consult

Drug-Induced Movement Disorder

N/A

Clinical Trials (1)

NCT06060444Evaluating a Telemedicine Neurological Consult Program for Drug-Induced Movement Disorders Using the RE-AIM Framework

N/A

Opicapone

Parkinson Disease

N/A

Clinical Trials (1)

NCT04787965Opicapone Treatment Initiation Open-Label Study

N/A

exposure to healthcare transition protocol

Congenital Adrenal Hyperplasia

N/A

Clinical Trials (1)

NCT07611786Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia

N/A

VY-AADC01

Idiopathic Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT03065192Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

Phase 1

NBI-98854

Tourette Syndrome

Phase 1

Clinical Trials (1)

NCT02256475Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome

Phase 1

Amphetamine

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT02959892A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)

Phase 1

DITEST

Male Hypogonadism

Phase 1

Clinical Trials (1)

NCT02966652Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism

Phase 1

Infacort

Adrenal Insufficiency

Phase 1

Clinical Trials (1)

NCT03178214Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral Administration

Phase 1

TAK-831 Oral Tablet

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04234672A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

Phase 1

Dexamethasone

Healthy

Phase 1

Clinical Trials (1)

NCT02408068Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Release on Fasting Only

Phase 1

Valbenazine

Tardive Dyskinesia

Phase 1

Clinical Trials (1)

NCT05053321Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine

Phase 1

TAK-831

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03687684Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects

Phase 1

Infacort®

Adrenal Insufficiency

Phase 1

Clinical Trials (1)

NCT03311932A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects

Phase 1

NBI-98854 50 mg capsule once daily

Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects

Phase 1

Clinical Trials (1)

NCT01910480Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects

Phase 1

TAK-831 T2

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03706469A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants

Phase 1

TAK-831

Healthy

Phase 1

Clinical Trials (1)

NCT02716987Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration

Phase 1

TAK-831 Tablet T2

Healthy

Phase 1

Clinical Trials (1)

NCT03224325A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

Phase 1

TAK-653 Placebo

Depressive Disorder

Phase 1

Clinical Trials (1)

NCT02561156TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants

Phase 1

Chronocort®

Adrenal Insufficiency

Phase 1

Clinical Trials (1)

NCT03343327A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects

Phase 1

Infacort

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT02777268Comparison of Pharmacokinetics of Infacort® Versus Immediate-release Hydrocortisone

Phase 1

NBI-98854 50 mg capsule

Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects

Phase 1

Clinical Trials (1)

NCT01916993Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency

Phase 1

Hydrocortisone

Congenital Adrenal Hyperplasia

Phase 1

Clinical Trials (1)

NCT03019614An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone

Phase 1

Chronocort

Adrenal Insufficiency

Phase 1

Clinical Trials (1)

NCT03051893A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort Formulations

Phase 1

Opicapone

Parkinson Disease

Phase 1

Clinical Trials (1)

NCT03496870A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.

Phase 1

NBI-77860

Congenital Adrenal Hyperplasia

Phase 1

Clinical Trials (1)

NCT02349503Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia

Phase 1

interleukin-4 PE38KDEL cytotoxin

Breast Cancer

Phase 1

Clinical Trials (1)

NCT00039052Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer

Phase 1

TAK-041

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT02748694Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

Phase 1

TAK-653

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03792672A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)

Phase 1

TAK-831 Oral Suspension

Schizophrenia, Cerebellar Ataxia

Phase 1

Clinical Trials (1)

NCT02566759A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

Phase 1

Hydrocortisone granules

Adrenal Insufficiency

Phase 1

Clinical Trials (1)

NCT01960530An Investigational Study of Hydrocortisone

Phase 1

TAK-831

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03101293A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

Phase 1

VY-AADC01

Parkinson's Disease

Phase 1

Elagolix

Folliculogenesis

Phase 1

Clinical Trials (1)

NCT01403038An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females

Phase 1

NBI-6024

Type 1 Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT00873561A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus

Phase 1

VY-AADC02

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT03562494VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

Phase 1

Chronocort

Congenital Adrenal Hyperplasia

Phase 1/2

Clinical Trials (1)

NCT00519818Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia

Phase 1/2

NBI-98854

Tardive Dyskinesia

Phase 2

Clinical Trials (1)

NCT01688037NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

Phase 2

NBI-921352

Focal Onset Seizure

Phase 2

Clinical Trials (1)

NCT05159908A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Phase 2

NBI-98854

Tardive Dyskinesia

Phase 2

Clinical Trials (1)

NCT01267188Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia

Phase 2

Placebo

Major Depressive Disorder

Phase 2

Clinical Trials (1)

NCT05203341Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)

Phase 2

NBI-1117568

Schizophrenia

Phase 2

Clinical Trials (1)

NCT05545111Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia

Phase 2

NBI-827104

Essential Tremor

Phase 2

Clinical Trials (1)

NCT04880616Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor

Phase 2

TAK-041

Stable Schizophrenia

Phase 2

Clinical Trials (1)

NCT03319953A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia

Phase 2

NBI-98854

Tourette Syndrome

Phase 2

Clinical Trials (1)

NCT03732534Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome

Phase 2

NBI-1065890

Tardive Dyskinesia

Phase 2

Clinical Trials (1)

NCT07365462Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

Phase 2

Luvadaxistat

Schizophrenia

Phase 2

Clinical Trials (1)

NCT03382639A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia

Phase 2

Valbenazine

Tourette Syndrome

Phase 2

Clinical Trials (1)

NCT03530293Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

Phase 2

NBI-827104

Epileptic Encephalopathy

Phase 2

Clinical Trials (1)

NCT04625101Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Phase 2

Neurocrine Biosciences(NBIX)

Should You Work at Neurocrine Biosciences?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (2)

Key Products by Revenue

Other Products (1)

Pipeline & Clinical Trials

Open Jobs (113)

Senior Investor Relations Manager

Principal Scientist, Medicinal Chemistry

Assoc. Director, Field Operations (Veeva CRM)

Associate Specialist, Clinical Trials Operations

Specialist, Clinical Data Management

NeuroPsych Account Specialist, Mobile AL

Senior Scientist, CMC Downstream Process Development

NeuroPsych Account Specialist, Olympia WA

Neuropsych Regional Specialty Manager, Arizona Metro

Long Term Care Account Specialist, York PA

Sr. Clinical Program Manager- Endo/Obesity

NeuroPsych Account Specialist, Boulder CO

NeuroPsych Account Specialist, Indianapolis S IN

NeuroPsych Account Specialist, Chicago Central

Senior Scientist, Analytical Development

Sr. Analyst, Stats Programming

Sr. Shipping & Receiving Specialist

TEMP - Toxicology Operations Specialist

Associate Engineering Director, Combination Drug Product/Device

Exec Director, API Synthetic Development

Senior Scientist, Analytical Development (Small Molecule)

Medical Director MD, Clinical Development, Endocrinology

NeuroPsych Regional Specialty Manager - Minneapolis Northwoods

Associate Analyst, Field Operations

Sr. Market Access Marketing Manager

Financials (FY2025)

Hiring Trend

Visa Sponsorship